The online version of this article (doi:10.1186/1475-2875-11-399) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing financial or non-financial interests.
RS and PY drafted the outline and the manuscript and participated in its design. RS coordinated inputs to the draft. All authors have read and approved the final manuscript.
The global demand for artemisinin-based combination therapy (ACT) has grown sharply since its recommendation by the World Health Organization in 2002. However, a combination of financing and programmatic uncertainties, limited suppliers of finished products, information opacity across the different tiers in the supply chain, and widespread fluctuations in raw material prices have together contributed to a market fraught with demand and supply uncertainties and price volatility. Various short-term solutions have been deployed to alleviate supply shortages caused by these challenges; however, new mechanisms are required to build resilience into the supply chain. This review concludes that a mix of strategies is required to stabilize the artemisinin and ACT market. First, better and more effective pooling of demand and supply risks and better contracting to allow risk sharing among the stakeholders are needed. Physical and financial buffer stocks will enable better matching of demand and supply in the short and medium term. Secondly, physical buffers will allow stable supplies when there are procurement and supply management challenges while financial buffer funds will address issues around funding disruptions. Finally, in the medium to long term, significant investments in country level system strengthening will be required to minimize national level demand uncertainties. In addition a voluntary standard for extractors to ensure appropriate purchasing and sales practices as well as minimum quality and ethical standards could help stabilize the artemisinin market in the long term.
Additional file 1: Analysis of approaches for better matching of ACT demand and supply.(DOCX 20 KB)12936_2012_2625_MOESM1_ESM.docx
Authors’ original file for figure 112936_2012_2625_MOESM2_ESM.pdf
Authors’ original file for figure 212936_2012_2625_MOESM3_ESM.pdf
Authors’ original file for figure 312936_2012_2625_MOESM4_ESM.pptx
WHO: WHO Urges Countries to Act on New Anti-Resistance Malaria Medicines. 2002, Geneva: World Health Organization, [ https://apps.who.int/inf/en/pr-2002-31.html]
WHO: Global supply of artemether-lumefantrine before, during, and after the Memorandum of Understanding between WHO and Novartis. May, 2011. 2012, Geneva: World Health Organization, [ http://www.who.int/malaria/diagnosis_treatment/finance/MoU_termination_report.pdf]
Grace C, Grupper M: Aligning ACT Supply and Demand: Short and Long Term Options. London: DFID Health Systems Resource Centre. 2005, London: Department for International Development
WHO: World Malaria Report 2011. 2012, Geneva: World Health Organization, [ http://www.who.int/malaria/world_malaria_report_2011/en/]
Harrison TP, Lee HL, Neale JJ: The practice of supply chain management: where theory and application converge. 2005, USA: Springer
UNITAID: Demand Forecast for Artemisinin-based Combination Therapies (ACTs) in 2012-2013 Q2-2012 Update. Prepared by the ACT Forecasting Consortium. 2012, Geneva: UNITAID, http://www.unitaid.eu/images/projects/malaria/ACT_Forecasting/ACT_Forecasting_Update_Q2-2012%20_25-July-12.pdf,
WHO: ACT Supply Task Force: Report to RBM Board. 2011. 2012, Geneva: World Health Organization, [ http://www.who.int/hiv/events/malaria_task_force_silvia2.pdf]
Dalberg Global Development Advisors: Independent Mid-Term Review of the Assured Artemisinin Supply System (A2S2) Project. 2012, Geneva: UNITAID, [ http://www.unitaid.eu/images/projects/malaria/110406_A2S2_Final_Report.pdf]
Assured Artemisinin Supply System: Launch of “Assured Artemisinin Supply System (A2s2)” Initiative 2009. 2012, http://www.a2s2.org/assets/files/Briefing_industry_v5.0.doc,
RBM/UNITAID/WHO: Artemisinin Conference Final Report. 2011, Hanoi, Vietnam, [ http://www.mmv.org/sites/default/files/uploads/docs/events/2011/2011_Artemisinin_Conference_Report.pdf]
Yadav P, Smith L, Alphs S: Technical Report. William Davidson Institute. Assessment of the effects of the Affordable Medicines Facility-malaria (AMFm) on market dynamics of API and ACTs at the global level. 2012, Ann Arbor, USA: University of Michigan
WHO: List of Prequalified Medicinal Products. 2012, Geneva: World Health Organization, [ http://apps.who.int/prequal/query/ProductRegistry.aspx?list=ma]
Dalrymple DG: Artemisia annua, Artemisinin, ACTs and Malaria Control in Africa: The Interplay of Tradition, Science and Public Policy, Working Paper. 2012, Geneva: Medicines for Malaria Venture, [ http://www.mmv.org/sites/default/files/uploads/docs/publications/Artemisia%20annua%20Artemisinin%20ACTS%20and%20Malaria%20control%20in%20Africa.Sept20.pdf]
Spar D, Delacey BJ: A), Harvard Business School Case Study 9-706-037. The Coartem Challenge. 2008, Boston, MA: Harvard Business School Publishing
Spar D: (B), Harvard Business School Case Study 9-707-025. The Coartem Challenge. 2008, Boston, MA: Harvard Business School Publishing
WSJ: Clinton Foundation Sets Up Malaria-Drug Price Plan. 2008, New York: Wall Street Journal
A2S2: Assured Artemisinin Supply System. 2012, Woerden, [ http://www.a2s2.org/index.php?id=76]
Strengthening Pharmaceutical Systems: A New Medicine Monitoring System Helps Prevent Antimalarial Stock-Outs in the Americas Region. Strengthening Pharmaceutical Systems Program. 2011, Arlington, VA: Management Sciences for Health
Supply Chain Management Solutions: Coordinated Procurement Planning Initiative. 2012, Geneva: World Health Organization, http://who.int/hiv/amds/scms_cpp_initiative.pdf,
Shretta R: US Agency for International Development by the Rational Pharmaceutical Management Plus Program. Global Fund Grants for Malaria: Summary of Lessons Learned in the Implementation of ACTs in Ghana, Nigeria, and Guinea-Bissau. 2007, Arlington, VA: Management Sciences for Health
Dhingra N: Review of Global Fund Round 8 Malaria Grant Signatures in 14 Sub-Saharan African Countries. 2009, Geneva: Roll Back Malaria Partnership
Global Fund: Board Approves Integration of AMFm into Core Global Fund Grant Processes. 2012, Geneva: The Global Fund News Release, [ http://www.org/theglobalfunden/mediacenter/newsreleases/2012-11-15_Board_Approves_Integration_of_AMFm_into_Core_Global_Fund_Grant_Processes/]
Rockwood J: LLIN Bottleneck Questionnaire-Updated Findings, RBM/Global Fund LLIN Procurement and Supply Management Workshop. 2009, Geneva: Roll Back Malaria Partnership
The Global Fund Office of the Inspector General: Audits and Investigations. 2012, Geneva: The Global Fund, http://www.theglobalfund.org/en/oig/reports/,
Editorial: Time for a “third wave” of malaria activism to tackle the drug stock-out crisis. PLoS Med. 2009, 6: e1000188-
Strengthening Pharmaceutical Systems: Strengthening Pharmaceutical Systems Program. Manual for Quantification of Malaria Commodities: Rapid Diagnostic Tests and Artemisinin-Based Combination Therapy for First-Line Treatment of Plasmodium Falciparum Malaria. 2012, Arlington, VA: Management Sciences for Health
DeRoeck D, Bawazir SA, Carrasco P, Kaddar M, Brooks A, Fitzsimmons J, Andrus J: Regional group purchasing of vaccines: review of the Pan American Health Organization EPI revolving fund and the Gulf Cooperation Council group purchasing program. Int J Health Plann Manage. 2006, 21: 23-43. 10.1002/hpm.822. CrossRefPubMed
Center for Pharmaceutical Management: Regional Pooled Procurement of Drugs: Evaluation of Programs. 2002, Arlington, VA: Management Sciences for Health
Burnett F: Reducing costs through regional pooled procurement, Essential Drugs Monitor 2003, Volume 32. 2003, Geneva: World Health Organization, 7-8.
Global Fund: Global Fund Board Decision Point GF/B23/DP9. 2012, Geneva: The Global Fund, [ http://www.theglobalfund.org/documents/board/23/BM23_DecisionPointsValueForMoneyMarketShaping_Report_en/]
Yadav P, Curtis K, Sekhri N: Mapping and realigning incentives in the global health supply chain: based on the supply chain for artemisinin combination therapy treatments for malaria. 2006, Zaragoza, Spain: MIT-Zaragoza International Logistics Program and the Healthcare Redesign Group Inc, [ http://www.cgdev.org/doc/DemandForecasting/RealigningIncentives.pdf]
Yadav P, Sekhri N, Curtis KA: Barriers to Access: An Assessment of Stakeholder Risks and Incentives in the Value Chain for Artemisinin Combination Therapy (ACT) Treatments (June 2007). 2012, Social Sciences Research Network, [ http://dx.doi.org/10.2139/ssrn.1008307]
Levine R, Pickett J, Sekhri N, Yadav P: Demand forecasting for essential medical technologies. Am J Law Med. 2008, 34: 2-3.
Anupindi R, Bassok Y: “Supply Contracts with Quantity Commitments and Stochastic Demand”. Quantitative Models for Supply Chain Management. Edited by: Tayur S, Magazine M, Ganeshan R. 1999, Boston, MA: Kluwer Academic Publishers
WHO: WHO Consultation on oral cholera vaccine (OCV) stockpile strategic framework: potential objectives and possible policy options. 2011, Geneva: World Health Organization, http://whqlibdoc.who.int/hq/2012/WHO_IVB_12.05_eng.pdf,
UNICEF: Supplies and Logistic. Vaccine Security. 2012, Copenhagen: United Nations Children’s Fund, [ http://www.unicef.org/supply/index_vaccine_security.html]
UNICEF: Annual Supply Report 2010. 2012, Copenhagen: United Nations Children’s Fund, [ http://www.UNICEF.org/supply/files/UNICEF_Supply_Annual_Report_2010_web.pdf]
UNICEF: Tender Strategy and Timeline [PowerPoint slides]. 2010. 2012, Copenhagen: United Nations Children’s Fund, [ http://www.unicef.org/supply/files/OPVTenderStrategy.pdf]
Vargas A, Yadav P: Evaluating the Costs and Benefits of Regional Distribution Hubs for HIV/AIDS. 2009, Zaragoza, Spain: MIT-Zaragoza Working Paper
SCMS: Regional Distribution Centers and Inventory Management. 2012, Arlington, VA: SCMS Technical Brief 2010 Supply Chain Management Systems, [ http://scms.pfscm.org/portal/pls/portal/!PORTAL.wwpob_page.show?_docname=2195390.PDF]
I+Solutions: ARV Access for Africa (AA4A). 2012, Woerden: I+Solutions, [ http://www.iplussolutions.org/index.php?id=6]
President’s Malaria Initiative: Working with Communities to Save Lives in Africa. 2009, Third Annual Report Washington DC: USAID
WHO Stop TB Department: Drug Resistant TB: Quarterly Newsletter of the Multidrug Resistant TB Working Group. 2008. 2012, Geneva: World Health Organization, [ http://www.stoptb.org/wg/mdrtb/assets/documents/MDR%20TB%20Newsletter%20April.pdf]
United Nations Foundation: The Pledge Guarantee for Health. 2012, Washington, DC: United Nations Foundation, [ http://www.unfoundation.org/what-we-do/campaigns-and-initiatives/pledge-guarantee-for-health/]
Hale V, Keasling JD, Renninger N, Diagana TT: Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. AmJTrop Med Hyg. 2007, 77: 198-202.
Anupindi R, Sivakumar S: ITC’s e-Choupal: A platform strategy for rural transformation. Business solutions for the global poor: Creating social and economic value. Edited by: Kasturi Rangan V, Quelch JA, Herrero G, Barton B. 2007, San Francisco, CA: Jossey-Bass, 173-182.
- Stabilizing supply of artemisinin and artemisinin-based combination therapy in an era of wide-spread scale-up
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II